Oxazolidinone antibiotics

Lancet

Volumn 358, Issue 9297, 2001, Pages 1975-1982

  Diekema, Daniel J ^a   Jones, Ronald N ^b  

^a UNIVERSITY OF IOWA   (United States)

^b Jones Microbiology Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL PROTEIN; CEFPODOXIME; CLARITHROMYCIN; DICLOXACILLIN; EPEREZOLID; GLYCOPEPTIDE; LINEZOLID; METICILLIN; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; NEW DRUG; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PNU 177553; POSIZOLID; RJW 334181; RJW 337813; RWJ 334181; RWJ 337813; STREPTOGRAMIN; UNCLASSIFIED DRUG; VANCOMYCIN; VCR 3808; VRC 3808;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; BACTERIOSTASIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENTEROCOCCUS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; TOXICITY;

EID: 0035830306     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06964-1     Document Type: Review

References (107)

1. Methicillin-resistant S aureus in US hospitals, 1975-1991
2. Emergence of vancomycin resistance in coagulase-negative staphylococci
3. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States
4. Emerging multiply resistant enterococci among clinical isolates I: Prevalence data from 97 medical center surveillance studies in the United States
5. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
6. Bacteremia due to viridans streptococci in neutropenic patients: A review
7. Survey of infections due to Staphylococcus sp: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific for the SENTRY Antimicrobial Surveillance Program, 1997-1999
8. Vancomycin-resistant enterococci
9. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
10. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989
11. Effect of quinupristin-dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort
12. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria
13. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative
14. Daptomycin disrupts membrane potential in growing Staphylococcus aureus
15. Oxazolidinones: New antibacterial agents
16. Oxazolidinones: A review
17. A novel antimicrobial agent joins the battle against resistant bacteria
18. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
19. Oxazolidinone antibacterial agents
20. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections
21. Mechanism of action of DuP-721: Inhibition of an early event during initiation of protein synthesis
22. Mechanism of action and in vitro studies of DuP-105 and DuP-721, new oxazolidinone antibacterials
23. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
24. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin
25. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
26. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
27. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
28. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci
29. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors
30. In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis
31. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
32. In vitro activities of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidemidis
33. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
34. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
35. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci
36. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains
37. Susceptibility testing with linezolid by different methods, in relation to published general breakpoints
38. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci
39. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
40. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
41. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci
42. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
43. European Committee on Antimicrobial Susceptibility testing (EUCAST). Linezolid breakpoints
44. Minimum inhibitory concentrations of oxazolidinones for Rhodococcus equi strains isolated from humans and animals
45. In vitro activity of linezolid against multiple Nocardia species
46. Susceptibilities of Mycoplasma hominis, Mpneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloscacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones
47. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
48. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid and linezolid
49. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans
50. In vitro antibiotic synergy against Flavobacterium meningosepticum: Implications for therapeutic options
51. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori
52. In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria
53. In vitro activity of linezolid and eperezolid against anaerobic bacteria
54. Oxazolidinones, a new class of synthetic antituberculous agent; in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis
55. In vitro activity of oxazolidinones against Mycobacterium avium complex
56. Linezolid, a new oxazolidinone, has activity in vitro and in macrophage culture system against Mycobacterium avium complex (MAC)
57. Activities of linezolid against rapidly growing mycobacteria
58. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity
59. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
60. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA
61. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid
62. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
63. Linezolid resistance in a clinical isolate of Staphylococcus aureus
64. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
65. Efficacy of linezolid in experimental otitis media
66. Linezolid therapy of vancomycin-resistant Enterocococcus faecium endocarditis
67. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillinresistant Staphylococcus aureus
68. Efficacy of linezolid in a staphylococcal endocarditis model
69. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days
70. Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days
71. Pharmacokinetics of linezolid in subjects with various degrees of renal function and on dialysis
72. Pharmocokinetics of linezolid in pediatric patients
73. Pharmacodynamic activity of an oxazolidinone in an animal infection model
74. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model
75. Emerging therapies for serious Gram-positive bacterial infections: A focus on linezolid
76. Linezolid is superior to cephalosporins in the treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
77. Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
78. Efficacy of linezolid in patients with nosocomial pneumonia based upon severity of illness as determined by baseline APACHE II score
79. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial
80. Randomized comparison of linezolid versus oxacillin/dicloxacillin for the treatment of complicated skin and soft tissue infections
81. Results of treating patients with significant, resistant, Gram positive intra-abdominal infections with linezolid
82. Outcomes of linezolid in patients with malignancies and significant, Gram-positive infections
83. Linezolid use in patients who are intolerant to or fail vancomycin
84. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus
85. Results of treating bone marrow transplant patients with linezolid in a compassionate use protocol for Gram-positive infections
86. Results of treating infective endocarditis with linezolid
87. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections
88. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms
89. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias
90. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid
91. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin
92. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid
93. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature
94. Successful treatment of disseminated mycobacterium chelonae infection with linezolid
95. Safety and efficacy of linezolid in eradication of nasal Staphylococcus aureus
96. New approaches to reduce Staphylococcus aureus nosocomial infection rates: Treating S aureus nasal carriage
97. Nasal carriage as a source of Staphylococcus aureus bacteremia
98. Linezolid for the treatment of community acquired pneumonia in hospitalised children
99. Although a novel microtiter-plate assay demonstrates that linezolid is a weak, competitive (reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed
100. Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using presso response to oral tyramine
101. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infection treated with linezolid or vancomycin: A randomized, multicentre trial
102. Synthesis and antibacterial activity of azolylphenyl oxazolidinones having carbon-bound 1,3-thiazolyl rings
103. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones. III: Activities against clinically important Gram-positive pathogens